MacroGenics’ breast cancer drug Margenza erases edge over Herceptin as it fails to extend lifenews2021-09-08T13:17:20+00:00September 8th, 2021|Fierce Pharma|
Another discount does the trick: Johnson & Johnson wins NICE backing for prostate cancer drug Erleadanews2021-09-08T13:12:43+00:00September 8th, 2021|Fierce Pharma|
On a dealmaking roll, Sanofi lays out $1.9B for Kadmon and its newly launched transplant drugnews2021-09-08T11:43:26+00:00September 8th, 2021|Fierce Pharma|
Science, science and more science: Pfizer and digital partners work to meet doctor demand for deep-dive datanews2021-09-08T03:47:09+00:00September 8th, 2021|Fierce Pharma|
Citius buys out license to Ontak replacement from Dr. Reddy’s for $40Mnews2021-09-07T18:53:01+00:00September 7th, 2021|Fierce Pharma|
Teligent pulls ‘super potent’ topical lidocaine lot following failed stability testsnews2021-09-07T15:46:55+00:00September 7th, 2021|Fierce Pharma|
Impel gets FDA nod to challenge Bausch for migraine marketnews2021-09-07T14:46:24+00:00September 7th, 2021|Fierce Pharma|
Roche’s Polivy to hit $2.4B as doctors expect ‘significant switching’ in newly diagnosed lymphoma: analystnews2021-09-07T14:43:59+00:00September 7th, 2021|Fierce Pharma|
Intarcia faces FDA refusal to approve as push to get diabetes delivery system to market enters endgamenews2021-09-07T14:42:34+00:00September 7th, 2021|Fierce Pharma|
Bristol Myers, Pfizer score another win in their Eliquis patent defense, protecting the blockbuster until 2028news2021-09-07T13:58:01+00:00September 7th, 2021|Fierce Pharma|
